Carrie Eglinton Manner
REPLIGENAbout Carrie Eglinton Manner
Carrie Eglinton Manner (age 51) is an independent director of Repligen Corporation, serving since 2020, and is currently President & CEO (and a director) of OraSure Technologies, Inc.; she holds a B.S. in Mechanical Engineering from the University of Notre Dame and brings 25+ years of leadership across diagnostics, medical devices, and life sciences at Quest Diagnostics and GE Healthcare . Her board skills matrix indicates strengths in public company leadership, risk oversight, manufacturing and global operations, strategic planning/M&A, life sciences technology, and commercial sales/marketing; she is an Audit Committee member (not chair) and is affirmatively classified as independent by the Board .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Quest Diagnostics | Senior Vice President, Advanced & General Diagnostics and Clinical Solutions; responsible for value creation across ~$10B clinical portfolio and growth in ~$2B Advanced Diagnostics | 2017–2022 | Led innovation in R&D, partnerships, and acquisitions; accelerated growth in specialty molecular/genetic offerings and pharma services |
| GE Healthcare | President & CEO of four global businesses in diagnostic imaging, lab services, and medical devices | 2009–2016 | Drove operations excellence, integrations, and profitability in units ranging from ~$150M to ~$3B revenue |
| GE Healthcare | Various roles of increasing scope (pre-2009) | Prior to 2009 | Built operating expertise across global businesses |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| OraSure Technologies, Inc. | President & CEO; Director | Joined June 2022 | Public diagnostics company (rapid tests, sample collection, molecular services) |
| Sapphiros | Board Director | Current | KKR-backed platform building next-gen diagnostic technologies |
| Team Pennsylvania | Board Director | Current | Non-profit focused on Pennsylvania’s long-term economic future |
| Thrive Networks | Board Director | Current | Non-profit focused on WASH, economic empowerment, gender equity, resilient communities in SE Asia |
Board Governance
- Committee assignments: Audit Committee member; Audit Committee met 6 times in FY2024; chair is Glenn P. Muir; all members meet SEC/Nasdaq independence standards .
- Independence: Board determined all nominees except CEO (Loeillot) and Executive Chair (Hunt) are independent; all committee members are independent .
- Attendance and engagement: Board met 6 times in FY2024; each director attended 100% of Board and applicable committee meetings, except one director (unnamed) who attended one of two committee meetings; all directors on the Board as of May 16, 2024 attended the 2024 Annual Meeting .
- Executive sessions: Independent directors hold executive sessions at each regular Board meeting; chaired by Executive Chair or Lead Independent Director as appropriate .
- Stock ownership/insider trading: Directors must hold 4× annual cash retainer within five years; restricted stock/RSUs count, options/PSUs do not; Board states all directors comply or are on track; anti-hedging/anti-pledging policy in place (hedging/derivatives/pledging not permitted without Audit Committee pre-approval) .
Fixed Compensation
| Component | Amount | Notes |
|---|---|---|
| Annual Board cash retainer | $60,000 | Non-employee director retainer |
| Audit Committee member fee | $10,000 | Member (non-chair) fee |
| Total cash fees earned (FY2024) | $70,000 | Reported for Eglinton Manner |
Performance Compensation
| Grant Type | Grant Date | Quantity/Terms | Grant-Date Fair Value | Vesting |
|---|---|---|---|---|
| Options | 5/16/2024 | 1,376 options @ $171.03 | $116,759 | Annual director awards vest in full on earlier of 1st anniversary or next Annual Meeting |
| RSUs | 5/16/2024 | 701 RSUs | $119,892 | Same vesting as above |
| Performance conditions | N/A | Director equity awards are time-based; no performance metrics | N/A | N/A |
The company does not use performance metrics for director equity grants; director awards are split evenly between RSUs and options and vest on a time basis .
Other Directorships & Interlocks
| Company | Overlap/Interlock Risk | Assessment |
|---|---|---|
| OraSure Technologies, Inc. | CEO and director at a diagnostics company | Different segment from Repligen’s bioprocessing tools; no related-party transactions >$120,000 disclosed; Audit Committee reviews related-party transactions; none since Jan 1, 2024 |
| Sapphiros | Board role at KKR-backed diagnostics platform | No disclosed transactions with Repligen; independence affirmed |
| Non-profits | Team Pennsylvania; Thrive Networks | No conflict exposure disclosed |
Expertise & Qualifications
- Public company CEO and board experience; risk oversight; manufacturing/global operations; strategic planning/M&A; life sciences technology & innovation; commercial sales/marketing (per Board skills matrix) .
- Built and led multi-billion-dollar businesses at GE Healthcare; scaled advanced diagnostics portfolios and R&D partnerships at Quest; integration and operations excellence track record .
- Mechanical Engineering degree (Notre Dame) .
Equity Ownership
| Metric | Amount | Details |
|---|---|---|
| Beneficial ownership (shares) | 10,712 | As of March 7, 2025; includes rights to acquire within 60 days |
| Ownership % of class | <1% | “Less than one percent” per company table |
| Options exercisable within 60 days | 7,920 | Included in beneficial ownership count |
| Unexercised options outstanding | 9,296 | As of 12/31/2024 (aggregate) |
| Unvested RSUs outstanding | 701 | As of 12/31/2024 |
| Stock ownership guideline | 4× annual cash retainer | RSUs count; options/PSUs do not; board indicates compliance/on-track |
| Hedging/pledging | Prohibited without pre-approval | Anti-hedging/anti-pledging policy; Audit Committee pre-approval required for any derivatives/hedging/pledging |
Governance Assessment
- Board effectiveness: Audit Committee membership provides financial reporting oversight; independence and strong attendance support investor confidence; executive sessions at each meeting reinforce independent oversight .
- Alignment: Director compensation mix is ~23% cash ($70k) and ~77% equity ($236.7k), encouraging long-term alignment through time-based RSUs/options; stock ownership guidelines further align interests .
- Conflicts/related-party exposure: No related-party transactions disclosed for directors/officers since Jan 1, 2024; OraSure/Sapphiros roles present low observable interlock risk given no disclosed transactions and independence confirmation .
- Shareholder signals: Company reports robust shareholder engagement and governance practices; prior say‑on‑pay approval ~94% (2023), indicating compensation framework support (context for overall governance) .
RED FLAGS
- None disclosed specific to Eglinton Manner: no related-party transactions, no delinquent Section 16 for her, no hedging/pledging noted; attendance generally 100% across directors with one unnamed exception not attributed to her .